Apigenin, the flavonoid concentrated in chamomile, parsley, and celery, has attracted growing interest for its mild sedative, anti-inflammatory, and NAD+-supporting properties. Supplement shelves now carry standalone apigenin capsules, and many wellness routines include chamomile tea daily. For most healthy adults, the risk profile looks modest. Pregnancy, however, changes every pharmacological calculation—what crosses the placenta, what influences uterine tone, and what disrupts fetal hormone signaling must all be weighed with far greater care.
Direct, controlled human trials on apigenin supplementation during pregnancy do not exist. What researchers and clinicians must work from instead is a patchwork of indirect evidence: studies on chamomile (apigenin’s richest dietary source), broader reviews of flavonoid supplements in pregnancy, animal toxicology data on structurally similar compounds, and mechanistic reasoning about apigenin’s known pharmacological actions. That patchwork, taken together, is enough to warrant real caution—even if it stops short of a definitive prohibition. This article assembles that evidence honestly, without overstating either the danger or the safety.
Key Takeaways
- Clinical studies on chamomile—apigenin’s richest source—link it to uterine contractions and labor onset, suggesting a biologically plausible mechanism for concern during pregnancy [PMID 28210497, PMID 30057060].
- A literature review of flavonoid supplements in pregnancy found that supplement-level doses cannot be assumed safe for the developing fetus, citing topoisomerase inhibition, placental transfer, and hormonal activity as concerns [1].
- Apigenin’s weak estrogenic activity and interaction with reproductive signaling pathways, as noted in endometriosis research [6], add a hormonal dimension to the pregnancy caution.
- Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4, which can raise blood levels of co-administered medications—a meaningful risk during pregnancy when polypharmacy is common.
- No direct, controlled human trials on isolated apigenin supplementation in pregnancy exist; the current evidence base is indirect and insufficient to establish safety at supplement doses.
What Apigenin Is and Why Pregnancy Changes the Risk Calculation
Apigenin (4′,5,7-trihydroxyflavone) is a naturally occurring plant flavonoid that exerts several pharmacological effects at meaningful doses. It binds to benzodiazepine recognition sites on GABA-A receptors, promoting sedation and anxiolysis. It inhibits cyclin-dependent kinases CDK2 and CDK6, triggering apoptosis in rapidly dividing cells. It also modestly inhibits the NADase enzyme CD38, which can support intracellular NAD+ levels. At typical dietary amounts from food, these effects are unlikely to reach clinically significant thresholds. At the concentrated doses found in modern supplements—often 50 mg to 100 mg per capsule—the picture becomes less certain.
Pregnancy amplifies every pharmacological concern in predictable ways. The developing fetus lacks the full complement of metabolic enzymes needed to process xenobiotics, so compounds that an adult clears quickly can accumulate in fetal tissue. Hormonal signaling is exquisitely sensitive during organogenesis and later stages of fetal brain development; flavonoids with weak estrogenic activity, including apigenin, may interfere with those signals. Uterine contractility is tightly regulated throughout pregnancy, and any agent that influences smooth muscle tone or prostaglandin pathways deserves scrutiny. Finally, the anti-proliferative activity that makes apigenin interesting for cancer research—inhibiting rapidly dividing cells—is the last thing wanted in a fetus whose entire development depends on rapid, coordinated cell division.
Chamomile, Apigenin's Primary Food Source, and Uterine Effects
Chamomile tea is the most common way people consume meaningful amounts of apigenin, and two clinical observations from chamomile studies are directly relevant to pregnancy. A study published in the Iranian Red Crescent Medical Journal found that chamomile administration was associated with the onset of labor in post-term pregnancies, suggesting a biologically plausible uterotonic effect [2]. While this was framed as a potential benefit for post-term induction, the same mechanism is clearly undesirable earlier in gestation when premature labor is the risk being guarded against.
A separate clinical trial examined the effect of chamomile odor—an aromatherapy exposure far lower than oral ingestion—on uterine contractions during the first stage of labor and found measurable effects on contraction patterns in primiparous women [3]. If aromatic exposure at that level registers a physiological signal, concentrated oral supplementation of the active compound carries commensurately higher concern. Taken together, these two studies do not establish that apigenin causes miscarriage or preterm labor, but they provide biological plausibility for uterine stimulation that makes high-dose apigenin supplementation during pregnancy difficult to recommend.
It is worth noting that neither study was designed to test apigenin in isolation, and chamomile contains many bioactive constituents beyond apigenin. Still, apigenin is the compound most frequently identified as responsible for chamomile’s pharmacological effects on smooth muscle, and the precautionary logic applies.
What Broader Flavonoid Research Suggests About Supplement Use in Pregnancy
A literature review published in Current Drug Targets examined whether flavonoid-based food supplements are safe for the developing child when taken during pregnancy [1]. The review identified several concerns: flavonoids can cross the placenta and reach fetal circulation; some flavonoids act as topoisomerase II inhibitors, raising theoretical concerns about infant leukemia risk at high doses; and the hormonal activity of various flavonoids—including their weak estrogenicity—may interfere with fetal reproductive development. The authors concluded that safety for the developing child cannot be assumed, and that supplemental doses above normal dietary exposure deserve scrutiny before being considered safe in pregnancy [1].
Apigenin was not the sole focus of that review, but it shares the structural and mechanistic features that drove the authors’ concerns. It is a polyphenol with weak estrogenic activity. It inhibits topoisomerase II in some assay systems. And at supplemental doses, it reaches concentrations well above anything achievable through food. This does not mean apigenin at those doses is definitively harmful—only that the mechanisms raising concern for the flavonoid class broadly are present in apigenin specifically.
Animal and Preclinical Data: Early Signals Worth Understanding
Preclinical toxicology data on apigenin itself in pregnancy is sparse, but data from structurally related flavonoids and plant extracts containing apigenin offer useful context. A prenatal developmental toxicity evaluation of Verbena officinalis—a flavonoid-rich herb—during gestation in Sprague-Dawley rats documented signs of developmental concern at higher doses, including effects on fetal body weight and placental parameters [5]. While Verbena contains a range of bioactive compounds and cannot be equated directly to isolated apigenin, the study illustrates that flavonoid-dense botanical preparations can produce measurable developmental effects in animal models.
A 2025 systematic review examining the impact of ginger extract and alpinetin on pregnancy outcomes in animal models found that certain plant-derived bioactives can alter fetal development parameters in ways that are dose- and timing-dependent [7]. The relevance to apigenin is indirect but instructive: plant compounds often considered gentle or natural do register pharmacological signals in pregnant animal models, and those signals are not always benign at higher doses.
Research on quercetin—a structurally related flavonoid—has examined its effects on hypertension and pregnancy-induced hypertension, finding both potential benefits and the need for careful dosing consideration during pregnancy [4]. Quercetin and apigenin share core flavonoid scaffold features and several mechanisms, so the cautious framing applied to quercetin in pregnancy applies by reasonable analogy to apigenin as well.
Hormonal and Endocrine Considerations
Apigenin has been identified in preclinical studies as a phytoestrogen—a plant compound that can bind estrogen receptors and modulate estrogen-dependent signaling. A review examining plants as potential therapies for endometriosis noted that several flavonoids, including apigenin, interact with estrogen receptor pathways in ways that can influence reproductive tissue [6]. During pregnancy, estrogen signaling governs placental development, fetal organ maturation, and the timing of parturition. Any exogenous compound that modulates estrogen receptor activity introduces a variable into that tightly choreographed system.
The concern is not that apigenin floods the system with estrogen the way synthetic hormones might. The concern is subtler: at supplemental concentrations, weak estrogenic or anti-estrogenic activity on fetal tissue—particularly during sensitive developmental windows—could have effects that are not immediately observable but matter downstream. Human data to quantify this risk does not exist for apigenin specifically, which is precisely why the precautionary argument holds weight.
Drug Interactions Amplified During Pregnancy
Apigenin inhibits cytochrome P450 enzymes CYP1A2, CYP2C9, and CYP3A4—the same enzymes responsible for metabolizing a wide range of medications commonly used or encountered during pregnancy. Nausea medications, antiepileptics, anticoagulants, and some antibiotics all pass through these pathways. Inhibiting them can raise plasma levels of co-administered drugs unpredictably, turning a therapeutic dose into a supratherapeutic one. During pregnancy, where dosing is already complicated by altered plasma volume, slower gastric emptying, and the pharmacokinetic needs of two individuals rather than one, adding an enzyme inhibitor raises the risk of unintended drug interactions considerably.
This concern applies to everyday co-exposures as well. Apigenin stacks poorly with other sedatives—melatonin, antihistamines, or alcohol—in any population. During pregnancy, where the sedative load reaching fetal circulation is a real concern, combining apigenin with other GABAergic agents amplifies the risk further. Anyone taking any prescription medication during pregnancy and considering apigenin supplementation should discuss the interaction risk with their prescribing physician before proceeding.
🛒 Where to Buy Apigenin
- Momentous Momentous ApigeninLab-tested / studied
capsules, 50 mg per capsule — Andrew Huberman’s publicly recommended brand; NSF Certified for Sport; single-ingredient, no fillers - Double Wood Supplements Apigenin 50mg
capsules, 50 mg per capsule, 120 count — High-volume value pick; third-party tested for purity; frequently top-ranked on Amazon - Nutricost Apigenin 50mg
capsules, 50 mg per capsule, 120 count — FDA-registered facility; gluten-free, non-GMO; competitive price-per-dose - Swanson Apigenin 50mg
capsules, 50 mg per capsule, 90 count — Established supplement brand; GMP-certified manufacturing; widely available, low cost
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The evidence reviewed here is indirect—no controlled human trials on isolated apigenin supplementation in pregnancy exist, and most data derives from chamomile studies, animal models, or analogous flavonoids. The absence of proof of harm is not proof of safety, particularly during pregnancy. Pregnant individuals, those trying to conceive, and those on medications metabolized by CYP1A2, CYP2C9, or CYP3A4 should consult a qualified healthcare provider before using apigenin supplements. These statements have not been evaluated by the FDA; apigenin is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
Is chamomile tea safe during pregnancy?
Chamomile tea is a common apigenin source, and two studies raise caution: one linked chamomile to labor onset in post-term pregnancies [2], and another found chamomile odor measurably affected uterine contractions during the first stage of labor [3]. Occasional, dilute chamomile tea is treated differently than concentrated apigenin supplements by most practitioners, but frequent or strong chamomile consumption during pregnancy is generally discouraged. Consult your midwife or OB for personalized guidance.
Can apigenin supplements cause miscarriage?
There are no controlled human studies that establish a direct causal link between apigenin supplementation and miscarriage. However, the uterotonic signals observed in chamomile studies [PMID 28210497, PMID 30057060] and the broader concerns about flavonoid supplements during pregnancy [1] provide biological plausibility for uterine effects. This does not prove causation, but it is sufficient reason to avoid high-dose supplementation—particularly in the first trimester—until more direct safety data exists.
Are all flavonoids equally risky during pregnancy?
No—the risk profile varies by compound, dose, and trimester. A literature review examining flavonoid-based supplements during pregnancy found that concerns include topoisomerase II inhibition and hormonal activity, but these differ in degree across the flavonoid family [1]. Research on related flavonoids like quercetin notes that dosing context matters significantly for pregnancy safety considerations [4]. Apigenin shares several of the concerning mechanisms, so it cannot be assumed safer than its class.
Does apigenin affect fetal hormones?
Apigenin has phytoestrogenic activity and has been noted to interact with estrogen receptor pathways in reproductive tissue contexts, as highlighted in research on plant-based approaches to endometriosis [6]. During fetal development, estrogen signaling governs organ formation and reproductive tract maturation. While the magnitude of apigenin’s estrogenic effect is modest compared to synthetic estrogens, the sensitivity of fetal tissue to hormonal signals means even modest interference is a theoretical concern worth taking seriously.
What about apigenin from food rather than supplements during pregnancy?
Dietary apigenin from parsley, celery, and chamomile tea represents a far lower and more variable dose than concentrated supplements. Most clinical nutrition guidance does not single out these foods as dangerous during pregnancy, and the studies raising concern involved chamomile in quantities that could reasonably be called medicinal rather than culinary [2]. That said, very large amounts of parsley have been associated with folkloric use as a uterine stimulant, and excessive intake of any apigenin-rich food during pregnancy is worth discussing with a healthcare provider.
Should I stop taking apigenin if I find out I'm pregnant?
If you are taking an apigenin supplement and discover you are pregnant, the prudent step is to stop the supplement and discuss the timing and dosage with your OB or midwife at the earliest opportunity. There is no emergency protocol needed for typical supplement doses, but given the lack of human safety data, the uterine stimulation signals in chamomile literature [PMID 28210497, PMID 30057060], and the general principle that supplement-level flavonoid doses should not be assumed safe in pregnancy [1], continuing supplementation throughout pregnancy without medical guidance is not advisable. This is informational, not medical advice.
References
- Barenys M et al. Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review. Current drug targets (2017). PMID 26240050
- Gholami F et al. Onset of Labor in Post-Term Pregnancy by Chamomile. Iranian Red Crescent medical journal (2016). PMID 28210497
- Heidari-Fard S et al. The effect of chamomile odor on contractions of the first stage of delivery in primpara women: A clinical trial. Complementary therapies in clinical practice (2018). PMID 30057060
- Ożarowski M et al. Pharmacological Effect of Quercetin in Hypertension and Its Potential Application in Pregnancy-Induced Hypertension: Review of In Vitro, In Vivo, and Clinical Studies. Evidence-based complementary and alternative medicine : eCAM (2018). PMID 30622610
- Fateh AH et al. Prenatal developmental toxicity evaluation of Verbena officinalis during gestation period in female Sprague-Dawley rats. Chemico-biological interactions (2019). PMID 30807743
- Meresman GF et al. Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies. Human reproduction update (2021). PMID 33124671
- Williams JT et al. Systematic review of the impact of ginger extract and alpinetin on pregnancy outcomes in animal models. BMC complementary medicine and therapies (2025). PMID 40380319
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
